ProPhase Labs initiates sale process for BE-Smart esophageal cancer test; updates on COVID-19 receivable collections

ProPhase Labs, Inc.

Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.
Crown Medical Collections: >60% of aggregate claims are from commercial payors that partially reimbursed, implying higher recovery rates.
Laboratory subsidiaries are in Chapter 11; legacy COVID-19 testing receivables being addressed via Crown Medical Collections initiative.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.